Harvard Bioscience President David Green to Present at Thomas Weisel Partners Healthcare Tailwinds Conference in Boston on September 8, 2005
HOLLISTON, Mass.--(BUSINESS WIRE)--Aug. 30, 2005--Harvard Bioscience, Inc., (Nasdaq: HBIO) today announced that its President, David Green, will present at the Thomas Weisel Partners Healthcare Tailwinds Conference at 8:35 am Boston time on Thursday September 8, 2005 at the Four Seasons hotel in Boston. The presentation audio will be simultaneously webcast and will be accessible from the HBIO website www.harvardbioscience.com under the "Presentations and Webcasts" tab, where it will also be archived or at http://www.veracast.com/webcasts/twp/hc2005/79202414.cfm Hardcopies of Mr. Green's presentation will be available at the conference or can be downloaded from our website by clicking on the investor presentation icon. Mr. Green will cover the historical and expected future performance of the business. After the presentation there will be a question and answer session. Some of the information to be presented by Mr. Green or provided in response to questions may contain information that has not previously been disclosed. Mr. Green will also be available to meet with interested investors. Requests for one-on-one interviews can be made by email to twpcorporateevents@tweisel.com or by calling (415) 364 2640.
Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells its products to thousands of researchers in 100 countries through its direct sales force, its 1,100 page catalog, various specialty catalogs and through its distributors, including GE Healthcare (formerly known as Amersham Biosciences), and Fisher Scientific. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Belgium, Austria and Germany and sales offices in France and Canada. For more information, please visit www.harvardbioscience.com.
The statements made in this press release, in the presentation and at the conference that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements include, but are not limited to, those factors set forth under the heading "Important Factors That May Affect Future Operating Results" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, Quarterly Report on Form 10-Q for the quarter ended June 30, 2005 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. The Company's financial guidance is given only as of the date of the relevant quarterly earnings press release and is not updated to the date of this press release or the date of the presentation.
CONTACT: Harvard Bioscience, Inc.
David Green, 508-893-8999
President
dgreen@harvardbioscience.com
SOURCE: Harvard Bioscience, Inc.
Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.